Facebook
Twitter
LinkedIn
Forward
Virtual Practice Managing Immune-Related Adverse Events (irAEs) in Simulated Scenarios
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: Varied
Overview
In this targeted AliveSim format, learners will be immersed in two scenarios to drive changes in clinical decision-making with irAEs. At the end of the activity, the learner will have completed two hands-on clinical experiences where they learn how to optimally manage irAEs with corrective mentoring from a virtual oncology expert. The design involves two irAE management scenarios that are similar and share the same clinical decision. The optimal choices in the decision will be different in each scenario allowing learners to recognize the optimal management patterns experts use.
Target Audience
Pharmacists, specialty nurses in cancer care, and advanced practice providers, specifically nurse practitioners and physician assistants in cancer care.
Learning Objectives
- Review both common and rare adverse events associated with immune checkpoint inhibitors (ICIs).
- Apply guideline recommended strategies to proactively identify, monitor, and manage immune-related adverse events (irAEs).
- Discuss the importance of the APP role in the collaborative approach for the identification and management of irAEs.
Commercial Support
This activity is supported by an educational grant from Merck Sharp & Dohme LLC.
Marianne Davies DNP, ACNP, AOCNP, FAAN
Associate Professor
Yale University
Yale School of Nursing
Oncology Nurse Practitioner-Thoracic & Solid Tumor
Senior Advanced Practice Provider II
Smilow Cancer Hospital at Yale-New Haven
Yale Comprehensive Cancer Center
New Haven, CT
Ms. Davies has no relevant financial information to disclose.
Conflict of Interest Disclosure Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Disclosure of Unlabeled Use
Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Available Credit
- 0.50 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above